Gilead Sciences - M&A Summary and Business Overview

Life ScienceCompany

Gilead Sciences M&A Summary

Gilead Sciences has acquired 24 companies, including 8 in the last 5 years. A total of 2 acquisitions came from private equity firms. It has also divested 3 assets.

Gilead Sciences’ largest acquisition to date was in 2020, when it acquired Immunomedics for $21.0B. It’s largest disclosed sale occurred in 2001, when it sold Gilead Oncology Business to OSI Pharmaceuticals for $200M. Gilead Sciences has acquired in 7 different US states, and 6 countries. The Company’s most targeted sectors include life science (96%) and chemicals (5%).

Gilead Sciences Business Overview

Where is Gilead Sciences headquartered?

Gilead Sciences is headquartered in Foster City, California.

What is Gilead Sciences’ revenue?

Gilead Sciences disclosed revenue of 27,116M USD for 2023 and 27,281M USD for 2022.

How many employees does Gilead Sciences have?

Gilead Sciences has 18,000 employees.

What sector is Gilead Sciences in?

Gilead Sciences is a life science company.

When was Gilead Sciences founded?

Gilead Sciences was founded in 1987.

M&A Summary

  • M&A Total Activity27
    • M&A Buy Activity24
    • M&A Sell Activity3
  • Total Sectors Invested 2
  • Total Countries Invested 6
  • M&A Buy/Sell Connections 7
  • M&A Advisors 17

Gilead Sciences

Gilead Sciences, Inc.

333 Lakeside Drive,
Foster City, California 94404
United States,
(650) 574-3000
www.gilead.com

Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead’s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases such as hepatitis B and C and serious cardiovascular/metabolic and respiratory conditions. Gilead Sciences was founded in 1987 and is Based in Foster City, California.


M&A Summary

Buy vs Sell

Year ≤ '19 '20 '21 '22 '23 '24 T
Buy (1.6/yr) # 16 5 - 1 1 1 24
vol $30.5B $27.2B $405M $4.3B $62.4B
Sell (0.0/yr) # 3 - - - - - 3
vol $206M $206M
  27

Most Recent M&A

Company Date Value Type
Cymabay Therapeutics, Inc. 2024-02-12 4.3B USD Add-on Acquisition
Newark, California · www.cymabay.com
XinThera LLC 2023-05-09 - Add-on Acquisition
San Diego, California · www.xinthera.com
MiroBio 2022-08-04 405M USD Add-on Acquisition
Oxford, United Kingdom · www.mirobio.com
MYR GmbH 2020-12-10 1.3B EUR Add-on Acquisition
Bad Homburg, Germany · www.myr-pharma.com
Immunomedics, Inc. 2020-09-13 21.0B USD Add-on Acquisition
Morris Plains, New Jersey · www.immunomedics.com
Tizona Therapeutics, Inc. 2020-07-21 - Add-on Acquisition
South San Francisco, California · www.tizonatx.com
Pionyr Immunotherapeutics, Inc. 2020-06-20 - Stake Purchase
South San Francisco, California · www.pionyrtx.com
Forty Seven, Inc. 2020-03-02 4.9B USD Add-on Acquisition
Menlo Park, California · www.fortyseveninc.com
Kite Pharma, Inc. 2017-08-28 11.9B USD Add-on Acquisition
Santa Monica, California · www.kitepharma.com
Gilead Sciences, Inc. - GS-6637 2017-02-16 - Divestiture
Foster City, California
View All >>

Business Unit M&A

Company Acquired Add-On/Sale Date #
Kite Pharma, Inc. 2017-08-28 Tmunity Therapeutics, Inc. 2022-12-20 2
Santa Monica, California · www.kitepharma.com Philadelphia, Pennsylvania · www.tmunity.com
Kite Pharma, Inc. 2017-08-28 Kite Pharma - Neoantigen TCR Cell Therapy R&D Platform & Manufacturing Facility 2021-07-19 1
Santa Monica, California · www.kitepharma.com Gaithersburg, Maryland
Arresto Biosciences, Inc. 2010-12-20 Aeon Bioscience, Inc. 2010-12-20 1
Palo Alto, California · www.arresto.com Birmingham, Alabama · www.aeonbio.com

M&A by Sector

Sector Buy # Value Sell # Value
Life Science 23 (96%) 62.3B (100%) 3 (100%) 206M (100%)
Chemicals 1 (4%) 130M (< 1%) - -
Total 24 $62.4B 3 $206M

By Geo

State/Country Buy Value Sell Value
United States 17 59.5B 3 206M
  California 8 22.7B 3 206M
  New Jersey 2 32.0B - -
  Colorado 2 3.1B - -
  Washington 2 740M - -
  North Carolina 1 464M - -
  Connecticut 1 120M - -
Canada 2 640M - -
  Ontario 1 510M - -
  Alberta 1 130M - -
Germany 2 1.8B - -
Denmark 1 65M - -
Ireland 1 47M - -
United Kingdom 1 405M - -
Domestic 17 (71%) 59.5B (95%) 3 (100%) 206M (100%)
Cross-border 7 (29%) 2.9B (5%) - -
Total 24 $62.4B 3 $206M

Top M&A Advisors

Financial Deals
BofA Securities
5
J.P. Morgan Securities
3
Goldman Sachs
2
Legal Deals
Skadden, Arps, Slate, Meagher & Flom
3
Mayer Brown
2
Gibson, Dunn & Crutcher
1

Deal Values

buy # Total
> $1B 8 $58.3B
$100M to $1B 11 $4.0B
< $100M 2 $112M
TOTAL $62.4B
Largest Immunomedics, Inc.
$21.0B (2020-09-13)
sell # Total
$100M to $1B 1 $200M
< $100M 1 $6M
TOTAL $206M
Largest Gilead Oncology Business
$200M (2001-12-21)

M&A Connections

Deals
Acquired from
Investor(s)
8%
2 (8%)
Strategic(s)
8%
2 (8%)
Divested to
Strategic(s)
100%
3 (100%)

 Subscribe to unlock this and 207,814
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 200K M&A Transactions
  • 203K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.